A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
Objective
The goal of this study is to generate real-world evidence about the safety and effectiveness of ORGOVYX in patients with prostate cancer in routine clinical care and the clinical course during treatment with and following cessation of ORGOVYX.
Eligibility
- Patients who are diagnosed with prostate cancer and initiating treatment with ORGOVYX at the time of enrollment or within 1 month prior to enrollment and who remain on treatment at enrollment.
- Patients who are willing and able to complete PRO assessments during the study
- Patients who have reviewed and signed the informed consent form (ICF)
NCT ID
NCT05467176
